TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06422507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg aflibercept (BAY 86-5321) (High Dose)
Description: High-dose (HD) aflibercept is the sponsor's study intervention under investigation. Dose formulation: solution in vial. Unit dose strength: 114.3 mg/mL, Dosage Level: 8 mg (70 µL), Route of Administration: Intravitreal (IVT) injection every 16 weeks following 3 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 3 mL glass vials. Each vial will be labeled as required per country requirement.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg aflibercept (EYLEA, BAY 86-5321)
Description: Aflibercept 2 mg is the sponsor's active comparator. Dose formulation: solution in vial. Unit dose strength: 40 mg/mL, Dosage Level: 2 mg (50 µL), Route of Administration: Intravitreal (IVT) injection every 8 weeks following 5 initial monthly doses. Packaging/ Labeling: Study Intervention will be provided in sterile 2 mL glass vials. Each vial will be labeled as required per country requirement. Aflibercept 2 mg for the non-study fellow eye treatment is considered an auxiliary medicinal product (AxMP) in this study. Fellow eye treatment will be allowed with 2 mg aflibercept, at the investigator's discretion for indications approved by governing authorities. The treated fellow eye will not be considered an additional study eye.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM).
Study: NCT06606964

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: The MRI examinations were conducted using a 1.5 Tesla closed MRI system with a body coil and spine coil. The participants\&#39; knees were positioned in full extension and their feet were in a neutral position during imaging. The scan was performed from the anterior superior iliac spine to the tip of the toes, and both legs were included in the field of view
Study: NCT06422507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: To preserve masking, sham injections will be performed for all participants at treatment visits in which participants do not receive an active injection through Week 56. Sham kits will be assigned for visits requiring sham injections. The sham kits are empty but should be handled in the same way as the active study intervention kits.~Sham injections will be given on visits when an active injection is not planned. During the study treatment period all participants will receive either an active injection (8 mg or 2 mg aflibercept) or a sham injection (for masking purposes) following their assigned treatment group and eligibility for Dose regimen modification (DRM).
Study: NCT05515536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatiquinone
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Study: NCT06425302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Specified dose on specified days
Study: NCT05012683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point Partial
Description: Patient is fit with Point Partial partial finger prosthetic system
Study: NCT05680272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: empathic communication-based education
Description: The study will consist of two stages. The first stage will be methodological in order to develop the Positive Birth Perception Awareness Scale based on Empathic Communication, and the second stage will be a trial model with a pretest-posttest control group in order to determine the effect of the training given to pregnant women based on empathic communication on positive birth perception awareness and birth experience.
Study: NCT04796337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: Sotatercept subcutaneous injection at a dose of 0.3 to 0.7 mg/kg.
Study: NCT06442514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PASS-IVR
Description: An intervention that includes a proactive telehealth intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain, and nightly Interactive Voice Response (IVR) calls to report smoking status, pain, and pedometer-measured step counts, which the clinician will use to provide individualized feedback.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Referral to the local smoking cessation VA clinic.
Study: NCT05552716

Intervention type: OTHER
Intervention: School safety tactics and policies
Description: A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.

Intervention type: OTHER
Intervention: School safety tactics and policies
Description: A list of school safety tactics and policies (such as metal detectors, armed security guards, active shooter drills) that were in place at the school at the time of shooting.
Study: NCT05033028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: SOAR (Smartphones for Opioid Addiction Recovery) system (battery + platform) as a tool for adjusting MOUD dosages to reduce treatment dropout.
Study: NCT06566833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: self assmbling peptide p11-4 combined with 0.05% fluoride
Description: biomimetic remineralizing agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate
Description: remineralizing agents that acts as a fluoride booster

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% sodium fluoride varnish
Description: remineralizing agent that is used as a gold standard for remineralization
Study: NCT04576156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat
Description: Imetelstat sodium will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Non-JAK-inhibitor treatment will be given, which may include but is not limited to hydroxyurea, thalidomide or an analog of thalidomide, interferon, danazol, hypomethylating agents, chemotherapy or radiotherapy.
Study: NCT05963698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN device
Description: Participants will undergo endovascular left atrial appendage occlusion with the WATCHMAN device
Study: NCT05583617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.~Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Substudy 2: Cevostamab will be administered intravenously (IV) on a 28-day cycle, up to a total of 13 cycles.~Substudy 4: Cevostamab will be administered by IV on a 21-day cycle, up to a total of 17 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered PO on days 1-21 of a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Iberdomide will be administered PO on days 1-14 of a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered on Days 2 and 8 of Cycles 1-3.
Study: NCT06287775

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo optional tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo optional tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo optional tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and urine sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT06322121

Intervention type: OTHER
Intervention: MRI
Description: Assessment of vascular reactivity and CAA/SVD MRI markers

Intervention type: OTHER
Intervention: MRI
Description: Assessment of vascular reactivity and CAA/SVD MRI markers

Intervention type: OTHER
Intervention: MRI
Description: Assessment of vascular reactivity and CAA/SVD MRI markers
Study: NCT06606964

Intervention type: OTHER
Intervention: Isokinetic Strength
Description: The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity

Intervention type: OTHER
Intervention: Isokinetic Strength
Description: The strength of the concentric knee extensor-flexor and concentric hip abductor-adductor muscles was measured using an isokinetic dynamometer at two different angular velocities: 60˚/sec and 180˚/sec. Three repetitions were performed at 60˚/sec, and five repetitions were performed at 180˚/sec. To calculate the H/Q ratio, we divided the peak concentric torque of the hamstrings by that of the quadriceps during the same contraction velocity. Similarly, to determine the Add/Abd ratio, we divided the peak concentric torque of the adductors by that of the abductors during the same contraction velocity
Study: NCT06287775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06556563

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Optune® device
Description: Optune® device delivering TTFields therapy at 200 kHz.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune® device
Description: Optune® device delivering TTFields therapy at 200 kHz.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Temozolomide per approved labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide per approved labeling.
Study: NCT06334471

Intervention type: OTHER
Intervention: no intervention needed
Description: no intervention needed
Study: NCT06601699

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation (TES)
Description: TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (TES)
Description: TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation with temporal interference (TES-TI)
Description: TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation with temporal interference (TES-TI)
Description: TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.
Study: NCT04726592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clorazepate Dipotassium
Description: Clorazepate Dipotassium : 20 mg intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoprofen
Description: Ketoprofen 100 mg IV
Study: NCT04693234

Intervention type: DRUG
Group type: OTHER
Intervention: Tislelizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: OTHER
Intervention: Tislelizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: OTHER
Intervention: Ociperlimab
Description: Administered as specified in the treatment arm
Study: NCT04982887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
Study: NCT06556563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
Study: NCT06565572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nL-FLVC-001
Description: nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
Study: NCT06249048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-001
Description: STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-001
Description: STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STX-001
Description: STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keytruda®
Description: Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
Study: NCT05451368

Intervention type: OTHER
Intervention: Coronary artery calcification lesions
Description: Calcification of atherosclerosis, a complex, organic, regulated and active process, is one of the manifestations of atherosclerosis. The progression of coronary atherosclerosis is a strong independent predictor of future coronary events. It has been shown that coronary artery calcification affects the healing of the neointima and the function of the endothelium after stenting. This may lead to changes in neointimal morphology and the development of neoatherosclerosis after stent implantation.
Study: NCT06249048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Keytruda®
Description: Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.
Study: NCT05213624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 764198
Study: NCT05748015

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: quantification of sensory and autonomic small nerve fibers by punch skin biopsy
Description: We'll perform a punch skin biopsy of 3mm from thigh, leg and fingertip and we'll quantify peripheral sensory and autonomic nerve fibers.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: quantification of sensory and autonomic small nerve fibers by punch skin biopsy
Description: We'll perform a punch skin biopsy of 3mm from thigh, leg and fingertip and we'll quantify peripheral sensory and autonomic nerve fibers.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Reflexes testing
Description: Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular Reflexes testing
Description: Cardiovascular reflex tests including deep breathing, head-up Tilt, standing, isometric exercises, mental arithmetic and Valsalva maneuver.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Description: We'll characterize patients' symptoms through the administration of clinical scales such as: COMPASS 31 autonomic symptoms scale; Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), the Pain Detect Questionnaire and the Total neuropathy score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of clinical scales evaluating autonomic symptoms, pain small fiber neuropathy symptoms
Description: We'll characterize patients' symptoms through the administration of clinical scales such as: COMPASS 31 autonomic symptoms scale; Small Fiber Neuropathy Symptom Inventory Questionnaire (SFN-SIQ), the Pain Detect Questionnaire and the Total neuropathy score